Holen Sie sich die Stockscreener-App
21.77
1.49%
0.32
Schlusskurs vom Vortag:
$21.45
Offen:
$21.47
24-Stunden-Volumen:
760.21K
Relative Volume:
0.91
Marktkapitalisierung:
$894.75M
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
15.01
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
+3.67%
1M Leistung:
+0.79%
6M Leistung:
-13.06%
1J Leistung:
-17.94%
1-Tages-Spanne:
$21.47
$22.45
1-Wochen-Bereich:
$20.79
$22.45
52-Wochen-Spanne:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.77 | 881.60M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Should you avoid Pacira BioSciences Inc stock right nowJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 - GlobeNewswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Does Pacira BioSciences Inc. have declining or rising EPSEarnings Beat & Real-Time Buy Signal Alerts - mfd.ru
Pacira BioSciences Highlights Positive Impact of NOPAIN Act on Non-Opioid Pain Management in New Survey Findings - Quiver Quantitative
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
AmacaThera Named Life Sciences Ontario Emerging Company of the Year - Bolsamania
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
2026-02-08 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
NJ Judge Tosses Pacira Investor Suit Over Patent Loss - Law360
2026-02-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out | NDAQ:PCRX | Press Release - Stockhouse
Avoiding Lag: Real-Time Signals in (PCRX) Movement - Stock Traders Daily
Pacira BioSciences officer Williams sells $269k in shares By Investing.com - Investing.com India
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com - Investing.com Nigeria
Pacira BioSciences SVP Lauren Riker sells $83k in stock - Investing.com
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences officer Williams sells $269k in shares - Investing.com
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-02-01 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
In A Strategic Move, Samit Hirawat Acquires Pacira BioSciences Stock Options Worth $9K: Enhancing Value - Benzinga
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Gap Down: What is Deluxe Corporations valuation compared to sectorQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com - Investing.com Nigeria
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Pacira BioSciences Inc.’s technical support levels2025 Sector Review & Technical Buy Zone Confirmations - mfd.ru
Pacira appoints Samit Hirawat to board of directors - TipRanks
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Pacira BioSciences appoints Samit Hirawat to board of directors - Investing.com
Bristol Myers drug development leader joins Pacira board - Stock Titan
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unveiling a 44.95% Potential Upside for Investors - DirectorsTalk Interviews
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):